Authors
Latest:
Challenges and Opportunities Bringing Lecanemab to Neurology Community ClinicsA group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
Latest:
Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MDThe resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]
Latest:
Addressing the Invisible Symptoms of Duchenne Muscular Dystrophy: Mathula Thangarajh, MD, PhDThe assistant professor at Virginia Commonwealth University provided comment on her presentation from AANEM 2023, and the need to raise awareness towards nonneuromuscular symptoms of Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]
Latest:
Ongoing Clinical Trials and the Future of ALSKey opinion leaders review the study design and mechanisms of action for drugs in ongoing clinical trials and consider the future of amyotrophic lateral sclerosis (ALS).
Latest:
The Road to Precision Medicine in Alzheimer Disease Through Biomarkers: Hans J. Moebius, MD, PhDThe chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]
Latest:
A Team Approach to Asleep Deep Brain StimulationHenry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.
Latest:
Next Steps in Expanding, Validating Capabilities of PrimSeq Digital Stroke Rehabilitation Tool: Heidi Schambra, MDThe associate professor in the Department of Rehabilitation Medicine at NYU Langone provided commentary on when the PrimSeq digital tool could see substantial impact on rehabilitation for stroke survivors and other neurological diseases. [WATCH TIME: 4 minutes]
Latest:
Taking on America’s Health Insurance Bureaucracy with AINeal K. Shah talked about an artificial intelligence innovation that can be used to fight denied health insurance claims, thus improving revenue cycle management for physicians practices and the patient experience.
Latest:
Practice Pearls for Management of NMOSDExperts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.
Latest:
Implementing Headache Training in ResidencyDespite a tremendous burden regarding migraine-related disability and expenditure, headache disorders remain underdiagnosed and undertreated, and only a small percentage of patients report satisfaction with the treatment received.
Latest:
AUPN 2022 Women Leaders in NeurologyLaurie Gutmann, MD; Gauri Pawar, MD; and Claire Henchcliffe, MD, discuss their own paths in medicine and observations of other women leaders. [WATCH TIME: 1 hour, 51 minutes]
Latest:
PPD/TFS Fostering Global Awareness in Rare DisordersRare Disease Day raises awareness for rare disorders, highlighting challenges, improving detection, and fostering collaboration for treatment advancements.
Latest:
Roundtable: The Future of Stereotactic and Functional NeurosurgeryTwo experts at Jefferson Health discuss several topics related to advances in neurosurgery, technology, and the future of minimally invasive procedures.
Latest:
Trichloroethylene Exposure and Usage, Environmental Associations in Parkinson Disease: Samuel M. Goldman, MD, MPHThe clinical professor in the department of neurology at the University of California, San Francisco, emphasized the need to restrict trichloroethylene availability and the challenges in studying environmental factors associated with Parkinson disease. [WATCH TIME: 4 minutes]
Latest:
AUPN Leadership Minute Episode 31: Recruitment and Retention of FacultyEpisode 31 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Adam Newsom, of Merritt Hawkins. [WATCH TIME: 5 minutes]
Latest:
Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Leigh Charvet, PhDThe professor of neurology at the NYU Grossman School of Medicine provided commentary on a study that demonstrated the benefits of using tDCS along with sleep language training to promote naming in primary progressive aphasia. [WATCH TIME: 5 minutes]
Latest:
The State of Coma Care: A Call for ActionOur moon shot to curing coma will take everyone. We all need to work together toward the grand challenge of awakening hope.
Latest:
Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBAThe chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]
Latest:
Understanding Patient Characteristics of Phase 3 APOLLOE4 Trial of ALZ-801 in Alzheimer Disease: John Hey, PhDThe chief scientific officer at Alzheon provided insight on the preliminary imaging findings of patients enrolled in the phase 3 APOLLOE4 study assessing ALZ-801 as a potential treatment for Alzheimer disease. [WATCH TIME: 3 minutes]
Latest:
Clinical Implications on the Influence of the Microbiome on Migraine Regulation: Blanca Marquez de Prado, PhDThe research project manager of the headache program at the Children's Hospital of Philadelphia discussed data that suggest that an unhealthy and imbalanced microbiome may exacerbate the frequency, severity, and duration of migraines. [WATCH TIME: 4 minutes]
Latest:
The Role of Nurse Practitioners in Multidisciplinary Stroke Care: Johanna L. Watkinson, APNThe acute care nurse practitioner at Overlook Medical Center spoke to the importance of having a multidisciplinary team when treating patients with stroke and the gaps that advanced practice providers can help fill.
Latest:
An Overview of Therapeutic Options for Amyotrophic Lateral SclerosisWith an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.
Latest:
Pediatric Sleep Disorders: Assessment and TreatmentThe long-term consequences of untreated—and prevalent—sleep disorders in children and adolescents point to a need for a focus on this field of care.
Latest:
In Memoriam: A Loving Tribute to June HalperNeurologyLive joins the CMSC in mourning the loss of founder and CEO,June Halper, MSN, APC-C, MSCN, FAAN.
Latest:
Retrospectively Exploring De-Escalation of Multiple Sclerosis Medication: Carolyn H. Goldschmidt, DOThe neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]
Latest:
Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MDThe professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]
Latest:
Episode 5: Emerging Women-Related Research and Closing ThoughtsThe group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.
Latest:
College Checklist for People Living With MigraineTransition to college life poses unique challenges for students living with migraine, and a comprehensive checklist helps ensure they are prepared for this critical phase.
Latest:
NeuroVoices: Anne Marie Morse, DO, FAASM, on the Impact of the Once-Nightly Sodium Oxybate Approval for Pediatric NarcolepsyThe director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital talked about how the recent approval of once-nightly sodium oxybate for pediatric narcolepsy enables more effective and manageable treatment options for children and families.
